Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation
Ara R, Pandor A, Stevens J, Rees A, Rafia R
Record ID 32008100359
English
Authors' recommendations:
Study found that rosuvastatin 40 mg/day is the most effective treatment in terms of lowering low-density lipoprotein cholesterol and is the optimal treatment for individuals with a recent history of acute coronary syndrome using a threshold of £20,000 per QALY. However, if the cost of atorvastatin decreases when the patent ends in 2011, atorvastatin 80 mg/day will become the most cost-effective treatment for all thresholds
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1700
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Adult
- Aged
- Aged, 80 and over
- Cost-Benefit Analysis
- Dose-Response Relationship, Drug
- Female
- Male
- Middle Aged
- Heart Diseases
- Hyperlipidemias
- Hypolipidemic Agents
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.